This off-label approach has become standard in obesity medicine, supported by clinical guidelines from major medical organizations
Unlike BPC-157 (which has zero registered US trials), tesamorelin has an extensive clinical trial history supporting its FDA-approved status
Si L, Fu J, Liu W, et al
Other than that, we have supervised exercise therapy, which does help patients but is broadly underutilized because its hard for many people to get to a gym three days a week to do supervised exercise. Procedures and surgery are also uncommon to treat peripheral artery disease, as these operations are often expensive and can have complications
About 68% of those who stuck with their treatment wound up with normal blood sugar levels, compared with 41% who stopped taking the drugs later in the study and 33% who stopped earlier
[1] The result is that the same gene can yield transcripts commonly labeled IGF-1Ea, IGF-1Eb, and IGF-1Ec, each carrying the identical mature IGF-1 core but a different tail